companydata.dkcompanydata.dk

XELLIA PHARMACEUTICALS ApS: Financial statements 2022

CVR: 61094628

Source: annual report 2022, Danish Business Authority

01/01/2022 – 31/12/2022

XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 2,245,303,000 and a net result of DKK -371,486,000 compared with DKK -503,090,000 the year before. That is an increase of 25.3% compared with the year before. The profit margin was -16.5%. Equity in the 2022 report amounted to DKK 1,750,675,000. The solvency ratio was 50.6%. The company had 648 employees in the financial year.

Revenue
DKK 2,245,303,000
Gross Profit
DKK 318,378,000
Profit/Loss
DKK -371,486,000
Equity
DKK 1,750,675,000
Total Assets
DKK 3,460,247,000
Employees
648

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
20222.2B318.4M-371.5M1.8B648
20211.8B-47M-503.1M2.1B640
20202B361.3M-115.7M2.6B624
20192.3B873.5M390.7M1.4B623
20181.9B576.7M-74.9M1B580

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on XELLIA PHARMACEUTICALS ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

XELLIA PHARMACEUTICALS ApS: The 2021 annual report is outApr 25, 2022

XELLIA PHARMACEUTICALS ApS has published its annual report for 2021. Revenue came to DKK 1,792,626,000, and the net result was DKK -503,090,000.

Lone Thiis joins the board of XELLIA PHARMACEUTICALS ApSMar 25, 2022

As of March 25, 2022, Lone Thiis has joined the board of directors of XELLIA PHARMACEUTICALS ApS.

Martin Bech joins the board of XELLIA PHARMACEUTICALS ApSMar 25, 2022

As of March 25, 2022, Martin Bech has joined the board of directors of XELLIA PHARMACEUTICALS ApS.

Gisli Lukas Ihlemann Lundahl joins the board of XELLIA PHARMACEUTICALS ApSMar 25, 2022

As of March 25, 2022, Gisli Lukas Ihlemann Lundahl has joined the board of directors of XELLIA PHARMACEUTICALS ApS.

Thomas Schou Hunderup leaves the board of XELLIA PHARMACEUTICALS ApSMar 25, 2022

As of March 25, 2022, Thomas Schou Hunderup has left the board of directors of XELLIA PHARMACEUTICALS ApS.

Lone Thiis leaves the board of XELLIA PHARMACEUTICALS ApSMar 24, 2022

As of March 24, 2022, Lone Thiis has left the board of directors of XELLIA PHARMACEUTICALS ApS.

About XELLIA PHARMACEUTICALS ApS

XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.

Source: annual report 2025, Danish Business Authority